Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENHANCE trial of prolonged-release fampridine in multiple sclerosis
NL-OMON41721Phase 3Active, not recruiting
- Sponsor
- Biogen
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Prolonged-release fampridine with Matched placebo (2 arms). Primary endpoint: Clinically meaningful improvement in patient-reported walking ability. Started Apr 2015; status: active, not recruiting.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON41721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41721.